Camperdown

Futó vizsgálatok

• Toboroz

  A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

  NCT07735637· 3. fázis· Forrás

• Toboroz

  A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07681596· 1/2. fázis· Forrás

• Toboroz

  A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

  NCT07652658· 2. fázis· Forrás

• Toboroz

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· 3. fázis· Forrás

• Toboroz

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· 3. fázis· Forrás

• Toboroz

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

  NCT06608927· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· 2. fázis· Forrás

• Toboroz

  Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT06350097· 3. fázis· Forrás

• Fut, nem toboroz

  Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

  NCT06109779· 3. fázis· Forrás

• Toboroz

  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  NCT06103864· 3. fázis· Forrás

• Toboroz

  A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  NCT05536141· 1. fázis· Forrás

• Fut, nem toboroz

  Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

  NCT05367440· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

  NCT04529772· 3. fázis· Forrás

• Fut, nem toboroz

  Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

  NCT04590963· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

  NCT04482309· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

  NCT04035486· 3. fázis· Forrás

• Fut, nem toboroz

  A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

  NCT03778957· 3. fázis· Forrás

• Fut, nem toboroz

  AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

  NCT02511106· 3. fázis· Forrás

• Fut, nem toboroz

  Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

  NCT01933932· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Mielóma multiplex3 toboroz
• Idiopátiás tüdőfibrózis1 toboroz
• Máj- és epeúti rák1 toboroz
• Petefészekrák1 toboroz
• Tripla negatív emlőrák1 toboroz
• Tüdőrák1 toboroz
• Vesedaganat1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

  NCT04642469· 3. fázis· Forrás

• Lezárult

  An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

  NCT04201262· 3. fázis· Forrás

• Lezárult

  AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT02296125· 3. fázis· Forrás